Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: +0.17% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $309.41 today, the market must believe free cash flow compounds 7.5%/yr for a decade (off $3.2B normalized FCF).
The market's 7.5% is more optimistic than its 9-yr track record.
2-stage DCF · 0.19B shares · net debt $3.3B
mean 10.2% · volatility σ 43% · implied rate exceeded in 3/9 yrs
Central path = implied 7.5%/yr growth; shaded band = ±1σ (43%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $321.33B 100.0% | $293.96B 100.0% | $262.17B 100.0% | $238.59B 100.0% | $213.99B 100.0% | $189.89B 100.0% | $179.59B 100.0% | $167.94B 100.0% | $153.14B 100.0% | $146.85B 100.0% |
| Cost of Revenue | $309.85B 96.4% | $284.05B 96.6% | $253.21B 96.6% | $230.29B 96.5% | $207.05B 96.8% | $184.70B 97.3% | $174.45B 97.1% | $163.33B 97.3% | $148.60B 97.0% | $142.58B 97.1% |
| Cost of Products | — | — | — | — | — | — | — | — | $148.60B 97.0% | $142.58B 97.1% |
| Gross Profit | $11.48B 3.6% | $9.91B 3.4% | $8.96B 3.4% | $8.30B 3.5% | $6.94B 3.2% | $5.19B 2.7% | $5.14B 2.9% | $4.61B 2.7% | $4.55B 3.0% | $4.27B 2.9% |
| Selling, General & Admin | $6.49B 2.0% | $5.66B 1.9% | $5.31B 2.0% | $4.85B 2.0% | $3.59B 1.7% | $2.77B 1.5% | $2.66B 1.5% | $2.46B 1.5% | $2.13B 1.4% | $2.09B 1.4% |
| Total Operating Expenses | $6.99B 2.2% | $6.09B 2.1% | $5.72B 2.2% | — | — | — | — | — | — | — |
| Operating Income | $2.63B 0.8% | $2.18B 0.7% | $2.34B 0.9% | $2.37B 1.0% | $2.35B 1.1% | -$5.14B -2.7% | $1.11B 0.6% | $1.44B 0.9% | $1.06B 0.7% | $1.53B 1.0% |
| Other Income (Expense), net | -$78.7M -0.0% | -$14.3M -0.0% | $49.0M 0.0% | $27.4M 0.0% | $41.7M 0.0% | $1.6M 0.0% | $13.0M 0.0% | -$25.5M -0.0% | $2.7M 0.0% | $5.0M 0.0% |
| Pretax Income | $2.26B 0.7% | $2.00B 0.7% | $2.16B 0.8% | $2.18B 0.9% | $2.22B 1.0% | -$5.29B -2.8% | $967.1M 0.5% | $1.18B 0.7% | $917.9M 0.6% | $1.39B 0.9% |
| Income Tax Expense | $690.5M 0.2% | $484.7M 0.2% | $428.3M 0.2% | $516.5M 0.2% | $677.3M 0.3% | -$1.89B -1.0% | $113.0M 0.1% | -$438.5M -0.3% | $553.4M 0.4% | -$37.0M -0.0% |
| Net Income | $1.55B 0.5% | $1.51B 0.5% | $1.75B 0.7% | $1.70B 0.7% | $1.54B 0.7% | -$3.41B -1.8% | $855.4M 0.5% | $1.66B 1.0% | $364.5M 0.2% | $1.43B 1.0% |
| Per Share | ||||||||||
| EPS (Basic) | $8.02 | $7.60 | $8.62 | $8.15 | $7.48 | $-16.65 | $4.07 | $7.61 | $1.67 | $6.73 |
| EPS (Diluted) | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 | $-16.65 | $4.04 | $7.53 | $1.64 | $6.32 |
| Weighted Avg Shares (Basic) | 193.8M | 198.5M | 202.5M | 208.5M | 205.9M | 204.8M | 210.2M | 217.9M | 218.4M | 212.2M |
| Weighted Avg Shares (Diluted) | 195.2M | 200.3M | 204.6M | 211.2M | 208.5M | 204.8M | 211.8M | 220.3M | 221.6M | 226.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 14% of free cash flow, leaving room to grow it and fund buybacks. Last year: $437M dividends + $435M buybacks = $873M returned on $3.2B FCF.
9 consecutive years of dividend increases · 6%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 17%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $4.4B covers the $115M due within a year 37.8× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-09-30 (8-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash of $4.4B fully covers short-term debt of $118M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 84th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.2× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 97.3 | 97.1 | 97.3 | 96.8 | 96.5 | 96.6 | 96.6 | 96.4 |
| Gross Profit | 2.7 | 2.9 | 2.7 | 3.2 | 3.5 | 3.4 | 3.4 | 3.6 |
| SG&A | 1.5 | 1.5 | 1.5 | 1.7 | 2.0 | 2.0 | 1.9 | 2.0 |
| Operating Income | 0.9 | 0.6 | -2.7 | 1.1 | 1.0 | 0.9 | 0.7 | 0.8 |
| Income Tax | -0.3 | 0.1 | -1.0 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
| Net Income | 1.0 | 0.5 | -1.8 | 0.7 | 0.7 | 0.7 | 0.5 | 0.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on COR: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| COR | $60.0B | 38.9× | 17.2× | 0.2× | 9.3% | 3.6% | 0.5% | 103% | 17.0% | 2.1× | 1 |
Peers = companies sharing COR's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.